Expanding Immunotherapy to Small Cell Lung Cancer
The FDA expanded the use of nivolumab to include treating certain patients with small cell lung cancer.
Progress Against Cancer
The FDA expanded the use of nivolumab to include treating certain patients with small cell lung cancer.
The FDA approved a new molecularly targeted therapeutic for treating certain patients with a rare form of leukemia called hairy cell leukemia.
The FDA expanded the use of a molecularly targeted therapeutic to treat patients with the most common type of liver cancer, hepatocellular carcinoma.
The FDA approved a combination of a molecularly targeted therapeutic and an immunotherapy for treating patients with Waldenström's macroglobulinemia.
The FDA approved a targeted radiotherapeutic for treating certain patients with two types of neuroendocrine tumors.
The FDA approved a new immunotherapeutic for treating certain patients with two rare types of non-Hodgkin lymphoma.
The FDA approved a new molecularly targeted therapeutic for treating certain patients with acute myeloid leukemia (AML).
The FDA approved a combination of two immunotherapeutics for treating patients with colorectal cancer.
The FDA approved two molecularly targeted therapeutics for use in combination to treat patients with metastatic melanoma.
The FDA approved a new anticancer therapeutic for treating certain patients with neuroendocrine tumors.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More